

Quarterly Activity Report and Appendix 4C

Doctor Care Anywhere Group PLC (ASX:DOC, “Doctor Care Anywhere” or “the Company”) is pleased to provide an update on trading and corporate activity for the quarter ended 30 September 2025 (“Q3 2025”)¹.

Executive Summary

- **Consultation Growth:** Year-on-year consultations rose 7.5% (excluding secondary care), driven by new service offerings and platform enhancements.
- **Service Expansion:** New clinical pathways launched in Mental Health, Musculoskeletal, and Skin Cancer care – differentiating our offer, and demonstrating to customers how we deliver accessible, patient-centred care at a lower cost.
- **Positive Cashflow Sustained:** £0.6m (A\$1.2m) net operating and investing cash inflow in Q3 2025 - our second consecutive quarter of positive cash generation. This compares to a £0.9m (A\$1.8m) outflow in Q3 2024 and £2.2m (A\$4.5m) inflow in Q2 2025.
- **Strong Cash Position:** £5.4m (A\$11.0m) cash on hand at quarter-end, providing a strong capital foundation for investing in business growth.
- **Guidance Reaffirmed:** Management reiterates medium-term targets, including revenue doubling over 3–5 years and a 15% EBITDA margin.

Operational Performance – KPIs

	Actual	% increase / (decrease) on	% increase / (decrease) on
	Q3 2025 000's	Q3 2024 (PcP)	Q2 2025 (QoQ)
Activated Lives ² at Period End	1,227.1	11.2%	(1.3%)
Consultations ³ in Period	170.1	4.6%	(3.4%)
Repeat Patients ⁶ in Period	126.4	8.5%	(2.3%)

¹ This Quarterly Activity Report and Appendix 4C is prepared in GBP in accordance with International Financial Reporting Standards in conformity with the requirements of the Companies Act 2006 (UK) and is unaudited. Figures expressed in Australian Dollars (“A\$”) have been converted from British Pounds Sterling at an exchange rate of AUD:GBP 1:0.49 for Q3 2025, 1:0.48 for Q2 2025 and 1:0.52 for Q3 2024.


² **Activated Lives** represents the total number of people who “sign up” for DOC’s service and enter their personal details.

³ **Consultations** is the number of GP and ANP consultations delivered to patients over the period.

⁵ **Secondary Care Journeys** is the number of secondary care journeys completed by patients over the period following a referral from an initial GP or ANP consultation on the DCA platform.

⁶ **Repeat Patients** represents the number of consultations completed by patients who had previously completed an appointment.

Consultations by Quarter (000's)



*Follow on appointments relate to DCA's secondary care pathway

Activated Lives reached 1.2 million, up 11.2% YoY, reflecting strong platform engagement. The slight QoQ dip (-1.3%) aligns with seasonal summer trends.

- Consultations rose 4.6% YoY, or 7.5% when excluding secondary care pathway appointments. QoQ decline (-3.4%) was seasonal.
- Repeat patients accounted for 74% of consultations—up 1 ppt QoQ and 3 ppt YoY—suggesting growing patient loyalty.

Growth drivers included:

- Expansion of services to include Physiotherapists and Mental Health Practitioners.
- Streamlined booking journey via the DCA app, significantly reducing time-to-book.

Cash Flow and Financial Performance

	Q3 2025 £000	Q2 2025 £000	% increase /(decrease) QoQ	Q3 2024 £000	% increase /(decrease) versus PcP
Cash movements					
Receipts from customers	9,319	10,930	(14.7%)	8,518	9.4%
R&D/Intellectual property costs	(1,264)	(1,299)	(2.7%)	(1,007)	25.5%
Operating costs	(4,459)	(4,558)	(2.2%)	(5,577)	(20.0%)
Other/Non-operating staff costs	(1,990)	(2,045)	(2.7%)	(2,167)	(8.1%)
Other administrative costs	(1,046)	(905)	15.6%	(877)	19.3%
Other cash inflows	84	46	82.6%	263	(68.0%)
Total operating and investing inflows/(outflows)	644	2,169	(70.3%)	(847)	176.1%

	Q3 2025 £000	Q2 2025 £000	% increase /(decrease) QoQ	Q3 2024 £000	% increase /(decrease) versus PcP
Cash movements					
Financing cash flows	-	(220)	(100.0%)	(23)	(100.0%)
Exchange loss	(2)	(1)	100.0%	(3)	(33.3%)
Net cash flow	642	1,948	(67.0%)	(873)	173.6%

Net cash inflow of £0.6m (A\$1.2m) marks the second consecutive quarter of positive cash generation.

- YoY improvement driven by higher receipts, reduced operating and staff costs, and productivity gains.
- QoQ decline reflects timing effects: a large customer catch-up receipt and annual subscription payment were booked in Q2.

The company ended Q3 with £5.4m (A\$11.0m) in cash; as it continues to strengthen its balance sheet quarterly it is investing actively in projects to differentiate its offer in the market and to grow and diversify its customer base.

Activities since previous market update

An update is provided on key operational and financial matters:

Product Expansion

- New digital treatment pathways have been launched for our three largest areas of clinical concern: Musculoskeletal, Skin Cancer, and Mental Health. Pilots are now live and will be rolled out rapidly based on feedback and learnings.
- Strategic review identified two high-potential markets: weight management and preventive health assessments. These digital-first propositions are in development and are expected to launch during Q4 2025. Both products have been designed to go to market via all three of our channels – direct-to-consumer, corporate programmes for employees and as part of insurance products.

Operating model transformation

Following H1 transformation, Q3 focused on converting efficiencies into profit and growth momentum.

- Streamlined operations and cost reductions are now delivering tangible benefits for patients and clients, while freeing up resources for growth.
- We are continuing to streamline operations and reduce costs to improve business profitability.

Medium Term Management Guidance

As presented at the AGM on 30 April 2025:

- Revenue target: £76m (A\$156m) within 3–5 years, doubling from £38m (A\$78m) in 2024.
- Implied CAGR: over 12%.
- EBITDA margin target: 15%

Other

As required by ASX Listing Rule 4.7C.3, the Company discloses that payments to related parties in the period totalled £0.14 million, representing payment of Director Fees to Executive and Non-Executive Directors (including pension and payroll tax payments).

This update must be read as a whole and is subject to the disclaimer that it:

- Is not a prediction or guarantee of future performance; and
- Involves known and unknown risks, uncertainties and other factors which are beyond the Company's control, and which may cause actual results to differ from this guidance. The Company is not liable for the accuracy and/or correctness of this information and any differences between the guidance and actual outcomes.

Corporate Overview

- 366,741,846 shares/CDIs on issue
- Market capitalisation of A\$49.51m at date of report release
- £5.4m (A\$11.0m) cash at 30 September 2025
- £10.6m (A\$21.6m) in face value of debt under the convertible loan at 30 Sep 2025, which matures in January 2028 and carries zero coupon (interest rate).

Niall Dore, Interim CFO, has prepared a short video of this Quarterly Report that you can view directly here: <https://investors.doctorcareanywhere.com/link/rLw4Qe>.

- ENDS -

This ASX announcement has been authorised for release by the Board of Directors.

Engage with the Doctor Care Anywhere management team directly by asking questions, watching video summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor hub here: <https://investors.doctorcareanywhere.com/announcements>

Subscribe to our news alert service: <https://investors.doctorcareanywhere.com/s/db4283>

About Doctor Care Anywhere:

Doctor Care Anywhere Group PLC is one of the UK's largest private providers of telehealth services. The Company works with insurers, healthcare providers and corporate customers to connect patients to a range of digitally enabled telehealth services on its proprietary platform. It is committed to delivering the best possible patient experience and clinical care through digitally enabled, joined up, evidence-based pathways.

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Name of entity

Doctor Care Anywhere Group PLC

ARBN

645 163 873

Quarter ended ("current quarter")

30 September 2025

Consolidated statement of cash flows		Current quarter £'000	Year to date (9 months) £'000
1.	Cash flows from operating activities		
1.1	Receipts from customers	9,319	28,556
1.2	Payments for		
	(a) research and development	(803)	(2,278)
	(b) product manufacturing and operating costs	(4,459)	(13,321)
	(c) advertising and marketing	(158)	(359)
	(d) leased assets	-	-
	(e) staff costs	(1,990)	(6,556)
	(f) administration and corporate costs	(867)	(3,578)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	7	11
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	342
1.8	Other (provide details if material)	78	193
1.9	Net cash from / (used in) operating activities	1,127	3,010

2.	Cash flows from investing activities		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(23)	(33)
	(d) investments	-	-
	(e) intellectual property	(460)	(1,629)

Consolidated statement of cash flows		Current quarter £'000	Year to date (9 months) £'000
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(g) entities	-	-
	(h) businesses	-	-
	(i) property, plant and equipment	-	-
	(j) investments	-	-
	(k) intellectual property	-	-
	(l) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received	-	-
2.5	Other	-	-
2.6	Net cash from / (used in) investing activities	(483)	(1,662)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	(321)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	-	(321)

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	4,789	4,407
4.2	Net cash from / (used in) operating activities (item 1.9 above)	1,127	3,010
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(483)	(1,662)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	(321)
4.5	Effect of movement in exchange rates on cash held	(2)	(3)
4.6	Cash and cash equivalents at end of period	5,431	5,431

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter £'000	Previous quarter £'000
5.1	Bank balances	5,431	4,789
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	5,431	4,789

6.	Payments to related parties of the entity and their associates	Current quarter £'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	142
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end £'000	Amount drawn at quarter end £'000
7.1	Loan facilities	10,610	10,610
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	Total financing facilities	-	10,610
7.5	Unused financing facilities available at quarter end		-
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well. The loan facility is as announced by the Company on 12 January 2024: https://wcsecure.weblink.com.au/pdf/DOC/02762058.pdf The Convertible Notes bear no interest and may be converted into CDIs by the Convertible Noteholders at any time (provided more than 60 days have passed since the holder's previous conversion) at an issue price of £0.0459 (equivalent to A\$0.0875, based on the exchange rate on 8 December 2023, being a premium of 94% to the closing price of the Company's CDIs on the ASX of A\$0.045 on 11 December). Doctor Care Anywhere may redeem all outstanding Convertible Notes in full on or after 1 January 2026 by repaying the outstanding principal.		

8.	Estimated cash available for future operating activities	£'000
8.1	Net cash from / (used in) operating activities (item 1.9)	1,127
8.2	Cash and cash equivalents at quarter end (item 4.6)	5,431
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	5,431
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	N/A
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>		
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions: 8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not? Answer:	

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 28 October 2025

Authorised by: Board of Directors